Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Rank in Stocks #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Share Price
$0.051239
Last synced: 2025-11-24
Market Cap
$1.38M
Change (1 day)
-4.48%
Change (1 year)
-54.57%
Country
NO
Trade BerGenBio ASA (BGBIO)

Category

Operating Margin for BerGenBio ASA (BGBIO)
Operating Margin as of 2026 TTM: 0.00%
According to BerGenBio ASA latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for BerGenBio ASA from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.97% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.